---
title: "Kiora Pharmaceuticals to Participate in Piper Sandler Virtual Ophthalmology Symposium | KPRX Stock News"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291536783.md"
description: "Kiora Pharmaceuticals (NASDAQ: KPRX) announced it will participate in an investor fireside chat at the Piper Sandler Virtual Ophthalmology Symposium on July 9, 2026. The live presentation will be available on the company's Investor Relations homepage, with a replay accessible for 90 days."
datetime: "2026-07-02T03:00:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291536783.md)
  - [en](https://longbridge.com/en/news/291536783.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291536783.md)
---

# Kiora Pharmaceuticals to Participate in Piper Sandler Virtual Ophthalmology Symposium | KPRX Stock News

See more from StockTitan in Google Search and AI answers.Adds StockTitan as a preferred source · opens Google

Add on Google

Encinitas, California--(Newsfile Corp. - July 2, 2026) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) today announced that it will participate in an investor fireside chat at the Piper Sandler Virtual Ophthalmology Symposium.

**Presentation Details**

**Date:** Thursday, July 9, 2026  
**Time:** 2:30 p.m. Eastern Daylight Time  
**Live Presentation:** Available on Kiora's Investor Relations homepage at ir.kiorapharma.com  
**Replay:** Available for 90 days on Kiora's Investor Relations Events page at ir.kiorapharma.com/news-events/events

**About Kiora Pharmaceuticals**

Kiora Pharmaceuticals is a clinical-stage biotechnology company developing advanced therapies for retinal disease. We target critical pathways underlying retinal diseases using innovative small molecules to slow, stop, or restore vision loss. KIO-301 is being developed initially for the treatment of retinitis pigmentosa, with potential to expand into choroideremia and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of macular edema due to retinal inflammation. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase (DHODH).

In addition to news releases and SEC filings, we expect to post information on our website, www.kiorapharma.com, and social media accounts that could be relevant to investors. We encourage investors to follow us on X and LinkedIn as well as to visit our website and/or subscribe to email alerts.

**Contact:**  
investors@kiorapharma.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/303675

### Related Stocks

- [KPRX.US](https://longbridge.com/en/quote/KPRX.US.md)
- [PIPR.US](https://longbridge.com/en/quote/PIPR.US.md)

## Related News & Research

- [KPRX Q2'26 Earnings: EPS estimate is (0.47) USD](https://longbridge.com/en/news/295096743.md)
- [Kiora Pharmaceuticals Inc 1Q 2026: Revenue ($2.4M), Net income ($2.42M), EPS ($0.58) — 10-Q Summary](https://longbridge.com/en/news/285713695.md)